$27.30
0.76%
Nasdaq, Nov 21, 10:00 pm CET
ISIN
US59045L1061
Symbol
MRSN

Mersana Therapeutics, Inc. Stock price

$27.30
+17.25 171.64% 1M
+18.47 209.09% 6M
-8.45 23.64% YTD
-22.20 44.85% 1Y
-131.70 82.83% 3Y
-569.45 95.43% 5Y
-322.70 92.20% 10Y
-322.70 92.20% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
-0.21 0.76%
ISIN
US59045L1061
Symbol
MRSN
Industry

Key metrics

Basic
Market capitalization
$136.5m
Enterprise Value
$80.1m
Net debt
positive
Cash
$56.4m
Shares outstanding
5.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.1 | 5.3
EV/Sales
2.4 | 3.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-6.6%
Return on Equity
727.7%
ROCE
-346.9%
ROIC
339.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$33.2m | $25.8m
EBITDA
$-66.3m | $-116.3m
EBIT
$-67.4m | $-75.4m
Net Income
$-70.1m | $-44.4m
Free Cash Flow
$-74.4m
Growth (TTM | estimate)
Revenue
-4.8% | -36.3%
EBITDA
14.8% | -62.2%
EBIT
15.2% | -2.9%
Net Income
6.1% | 35.8%
Free Cash Flow
22.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-199.8% | -450.7%
EBIT
-203.1%
Net
-211.2% | -172.2%
Free Cash Flow
-224.1%
More
EPS
$-14.0
FCF per Share
$-14.9
Short interest
7.1%
Employees
102
Rev per Employee
$400.0k
Show more

Is Mersana Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,052 stocks worldwide.

Mersana Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Mersana Therapeutics, Inc. forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Mersana Therapeutics, Inc. forecast:

Buy
87%
Hold
13%

Financial data from Mersana Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
33 33
5% 5%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
25% 25%
95%
- Research and Development Expense 69 69
4% 4%
208%
-66 -66
15% 15%
-200%
- Depreciation and Amortization 1.09 1.09
35% 35%
3%
EBIT (Operating Income) EBIT -67 -67
15% 15%
-203%
Net Profit -70 -70
6% 6%
-211%

In millions USD.

Don't miss a Thing! We will send you all news about Mersana Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mersana Therapeutics, Inc. Stock News

Neutral
Business Wire
8 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics, Inc. (NasdaqGS: MRSN) to Day One Biopharmaceuticals, Inc. Under the terms of the proposed transaction, shareholders of Mersana will receive $25.00 per share in cash plus one n...
Neutral
Seeking Alpha
11 days ago
Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Michael Vasconcelles - Head of Research & Development Charles York - COO & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Gr...
Neutral
PRNewsWire
11 days ago
MILWAUKEE , Nov. 13, 2025 /PRNewswire/ -- The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Day One Biopharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
More Mersana Therapeutics, Inc. News

Company Profile

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in oncology indications. Its product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC) and XMT-1536, which focuses on ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Head office United States
CEO Martin Huber
Employees 102
Founded 2001
Website www.mersana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today